The FDA accepted Intellia’s BLA for lonvo-z and granted Priority Review, setting a March 10, 2027 target action date. For investors, the application now has a defined regulatory milestone, while approval could make lonvo-z the world’s first in vivo CRISPR-based therapy and only one-time HAE treatment.
Key Highlights
- The FDA set a March 10, 2027 PDUFA target action date for lonvo-z.
- The agency is not currently planning an advisory committee meeting for the application.
- In Phase 3 data, lonvo-z reduced mean monthly HAE attacks by 87% versus placebo.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) has secured FDA acceptance and Priority Review for its Biologics license application for lonvoguran ziclumeran, or lonvo-z. The application is supported by trial data showing an 87% reduction in mean monthly hereditary angioedema attacks versus placebo. The FDA set March 10, 2027, as the PDUFA target action date.
FDA Review Advances Without Advisory Committee
The FDA has told Intellia that it is not currently planning an advisory committee to discuss the application. The BLA covers lonvo-z for hereditary angioedema, a rare genetic disease marked by severe, recurring and unpredictable inflammatory attacks. The therapy was previously known as NTLA-2002. The application is supported by results from Intellia’s global Phase 3 HAELO trial.
Phase 3 Data Show Treatment-Free Response
During the efficacy evaluation period, lonvo-z produced an 87% reduction in mean monthly attacks compared with placebo, with p<0.0001.
FAQs
Q: What is the FDA status of Intellia’s lonvo-z BLA?
A: The FDA accepted Intellia’s biologics license application for lonvo-z and granted Priority Review. The PDUFA target action date is March 10, 2027.
Q: What did the lonvo-z Phase 3 trial show?
A: Lonvo-z reduced mean monthly hereditary angioedema attacks by 87% versus placebo. Also, 62% of treated patients were attack free and HAE therapy free, compared with 11% for placebo.
Q: Could lonvo-z become the first CRISPR therapy?
A: If approved, lonvo-z would be the world’s first in vivo CRISPR-based therapy. Intellia also describes it as the only one-time treatment for hereditary angioedema.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.